tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Aquestive Therapeutics Reports Q2 2025 Financial Results

Story Highlights
  • Aquestive Therapeutics is advancing Anaphylm, a sublingual epinephrine film, with potential U.S. launch in 2026.
  • Aquestive reported a $13.5 million net loss in Q2 2025, due to decreased revenues and increased expenses.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Aquestive Therapeutics Reports Q2 2025 Financial Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Aquestive Therapeutics ( (AQST) ) is now available.

Aquestive Therapeutics announced its second quarter 2025 financial results and business updates, highlighting the FDA’s acceptance of their New Drug Application for Anaphylm, a sublingual film epinephrine product. The company is preparing for a potential U.S. launch in 2026 and is also pursuing regulatory engagements in Canada and the EU. Aquestive aims to address unmet needs in emergency allergy treatment with Anaphylm, which offers advantages over existing epinephrine therapies. Financially, the company reported a net loss of $13.5 million for the second quarter of 2025, attributed to decreased revenues and increased expenses.

The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.

Spark’s Take on AQST Stock

According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.

The overall stock score is primarily influenced by the company’s challenging financial performance, characterized by declining revenues, negative profit margins, and high leverage. Although the technical analysis suggests positive momentum, the valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with strategic progress for Anaphylm, but significant financial challenges persist.

To see Spark’s full report on AQST stock, click here.

More about Aquestive Therapeutics

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies. The company specializes in developing non-invasive drug delivery systems, with a market focus on improving patient experiences and accessibility to treatments.

Average Trading Volume: 1,486,131

Technical Sentiment Signal: Strong Buy

Current Market Cap: $387.4M

For detailed information about AQST stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1